Corticosteroid drugs, such as dexamethasone and prednisolone, are among the most prescribed drugs in the world. These immune-suppressive drugs are very effective against inflammatory and auto-immune diseases, such as asthma, psoriasis, inflammatory bowel disease and rheumatoid arthritis. However, their use is limited by their side effects, which are severe and include osteoporosis, elevated blood sugar levels, mood swings and insomnia.
To address these issues, we modified the structure of prednisolone by adding a sugar group, creating a new compound called gentiobiose-prednisolone. In preclinical studies using zebrafish and mouse models, this novel drug demonstrated anti-inflammatory effects comparable to prednisolone, but with significantly reduced side effects.
We believe gentiobiose-prednisolone has the potential to become a next-generation corticosteroid, offering relief to patients who currently suffer from the side effects of corticosteroids or those unable to use these drugs due to contraindications. Through the Biotech Booster program, we will further investigate its molecular mechanisms, using both in vitro and in vivo models. We will also explore whether additional modifications are necessary to optimize its therapeutic potential and evaluate its commercial viability. Given that an estimated 1% of the population in Western countries chronically uses corticosteroids, the development of gentiobiose-prednisolone could have a profound impact on patient care.
